View all the latest information in myeloproliferative neoplasms, arranged by therapeutic class and intervention. Listed below are recently updated therapeutic classes.
Promising preclinical data on combined JAK, PIM, and CDK4/6 inhibition in MPN
Ruxolitinib, a selective inhibitor of Janus kinase 1/2 (JAK1/2), has proven to be beneficial to patients with...
What is the impact of pre-treatment ruxolitinib on patients with MF receiving allo-HSCT? An EBMT CMWP study
Most patients (89%) diagnosed with myelofibrosis (MF) present with splenomegaly, and new or...
COVID-19 vaccination for hematopoietic stem cell transplant patients
The SARS-CoV-2 pandemic has changed the world over the last year and impacted almost every part of our lives. In particular,...
DRSS: A new disease risk stratification system for hematologic malignancies
The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is largely dependent upon disease type and...
Does extreme thrombocytosis in patients with low-risk essential thrombocythemia increase the risk of thrombotic events and benefit from specific therapy? A retrospective analysis
Treatment outcomes with pegylated interferon in young patients with PV/ET
Myeloproliferative neoplasms (MPN) are very rare in young patients compared with adults. Not surprisingly, diagnostic...
Givinostat in polycythemia vera: Long-term safety and efficacy
Polycythemia vera (PV) is a BCR-ABL1-negative subtype of myeloproliferative neoplasms (MPN), characterized by excessive erythroid...
Results from an ongoing phase II study of IMG-7289 (bomedemstat) in patients with advanced MF
Many patients with myelofibrosis (MF) become intolerant or resistant to currently approved JAK inhibitors,...
Non-steroidal anti-inflammatory drugs
PI3 kinase inhibitors